

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**微創醫療科學有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 00853)**

## **GRANT OF SHARE OPTIONS**

This announcement is made pursuant to Rule 17.06A, Rule 17.06B and Rule 17.06C of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The board (the “**Board**”) of directors (the “**Director(s)**”) of MicroPort Scientific Corporation (the “**Company**”) has granted an aggregate of 18,027,634 share options (the “**Share Option(s)**”) under the share option scheme adopted by the Company on 18 June 2020 (the “**Share Option Scheme**”) to 76 eligible participants (the “**Grantees**”), who are employees of the Group, subject to the acceptance of the Share Options by the Grantees, to subscribe up to an aggregate of 18,027,634 ordinary shares of the Company (the “**Share(s)**”) of US\$0.00001 each, representing approximately 0.99% of the issued share capital of the Company as at the date of this announcement.

Details of the Share Options granted are as follows:

Date of grant	: 31 March 2023
Number of the Share Options granted:	: an aggregate of 18,027,634 Share Options, each Share Option entitling the holder of the Share Option to subscribe for one Share at the exercise price
Exercise price of the Share Options granted	: HK\$20.01 per Share
Closing price of the Shares on the date of grant	: HK\$18.46 per Share

The average closing price of the Shares for the five trading days immediately preceding the date of grant	: HK\$20.01 per Share
Validity period of the Share Options	: 10 years from the date of grant (i.e. 31 March 2023 to 30 March 2033 (both days inclusive))
Vesting period of the Share Options	: among the total Share Options: <ul style="list-style-type: none"> <li>(i) 2,775,936 Share Options shall be vested on the fifth anniversary of the date of grant (i.e. 31 March 2028); and</li> <li>(ii) 2,251,698 Share Options shall be vested in the following manners: half of the 2,251,698 Share Options shall be vested on 31 March 2025, and the rest shall be vested in tranches on the last day of each month during the period from April 2025 to March 2027 (inclusive). The total 2,251,698 Share Options shall be fully vested on the last day of March 2027; and</li> <li>(iii) 13,000,000 Share Options shall be vested in the following manners: 2,600,000 Share Options shall be vested twelve months after the date of grant, and 2,600,000 additional Share Options shall be vested on each anniversary of the vesting commencement date thereafter.</li> </ul>
Consideration for the grant	: US\$1.00 to be paid by the Grantee upon acceptance of the Share Options granted
Performance target	: There is no performance target attached to the Share Options granted.

The purpose of the Share Option Scheme is to provide the Company with a means of incentivizing the eligible participants and retaining employees, and to encourage employees to work towards enhancing the value of the Company and promote the long-term growth of the Company. The number of Options to be granted are based on the work performance and potential contributions of the Grantees and no additional performance target is imposed before the Options are vested to the Grantees. In view of the above, the remuneration committee of the Company considered the grant of Options aligned with the purpose of the Share Option Scheme.

Clawback mechanism : The Share Options granted were subject to the clawback mechanism as set out in the terms of the Share Option Scheme, in particular, the lapse of the Share Options upon cessation of employment of the Grantee and the cancellation of Share Options at the discretion of the Board.

To the best knowledge of the Directors, save as disclosed in this announcement, (i) none of the grantees is a director, chief executive or substantial shareholder of the Company or an associate (as defined under the Listing Rules) of any of them; (ii) none of the grantees is a participant with Share Options granted and to be granted exceeding the 1% individual limit under the Listing Rules; (iii) none of the grantees is a related entity participant or a service provider (as defined under the Listing Rules).

#### **NUMBER OF SHARES AVAILABLE FOR FUTURE GRANT**

After the above grant of Share Options, 92,798,587 remaining Shares will be available for future grant under the existing scheme mandate limit of the Share Option Scheme.

By order of the Board  
**MicroPort Scientific Corporation**  
**Dr. Zhaohua Chang**  
*Chairman*

Shanghai, the People's Republic of China, 31 March 2023

*As at the date of this announcement, the executive Director is Dr. Zhaohua Chang; the non-executive Directors are Mr. Norihiro Ashida, Dr. Yasuhisa Kurogi and Mr. Hongliang Yu; and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.*

\* *For identification purpose only*